Abstract:Objective To study dendritic cells(DC)precursors that were mobilized into the pe- ripheral blood by injection of macrophage inflammation protein-1α(MIP-1α)and the anti-tumor effects induced by MIP-1αmobilized DC vaccine expressing tumor antigen in vivo.Methods 615 mice were in- jected with MIP-1αvia the tail vein.B220~-CD11c~+cells were sorted from the peripheral blood mononu- clear cells(MNCs)by FACS.The quantitive change of B220~-CD11c~+cells were compared among MNCs.Freshly isolated B220~-CD11c~+cells and B220~-CD11c~+cells cultured with mouse granulocyte- macrophage colony-stimulating factor(mGM-CSF),interleukin 4(IL-4),and mouse tumor necrosis factor-α(mTNF-α)were analyzed by phenotype analysis,and mixed lymphocyte reaction(MLR).For adenovi- ral(Ad)-mediated gene transduetion,cultured B220~-CD11c~+cells were incubated with Ad-melanoma antigen gene-3.B220~-CD11c~+cells pulsed mouse forestomach carcinoma cells(MFC)tumor lysate was used as control.To establish the solid tumor model,groups of 615 mice were injected with MFC cells sub- cutaneously in the abodminal wall.DC vaccines were immunized after the challenge of MFC cells,then the tumor size and the survival of mice which could detect the anti-tumor effects of DC vaccines were ob- served.Results B220~-CD11c~+cells were increased in the circulation 8 h after MIP-1αinjection, then gradually reached a peak level 48 h after injection,accounting for(13.68±0.95)% among MNCs. Freshly isolated B220~-CD11c~+cells did not show the characters of mature DC,while cultured B220~- CD11c~+cells were phenotyically identical to typical DC and gained the capacity to stimulate allogeneie T cells.These MIP-1αmobilized DCs were transduced with Ad-MAGE-3,which were prepared for DC vac- cines expressing tumor antigen.Five days after the challenge of MFC cells,mice were subsequently injected with DC vaccines.The.tumor size in the experimental group was much smaller than that in the control groups 27 days after the challenge.Kaplan-Meier survival curves revealed that the survival of the mice in the experimental group was much longer than that in the control groups(P<0.01).Conclusion B220~- CD11c~+DC precursors were rapidly accumulated in the peripheral blood after injection of MIP-1αin mice,which could further differentiate into mature DCs.These MIP-1αmobilized DCs,when transduced with MAGE-3 gene,could generate therapeutic anti-tumor effects on MFC cells loading mice in vivo.The efficiency of anti-tumor immunity induced by MIP-1αmobilized DCs expressing tumor antigen were much more potent than MIP-1αmobilized DCs pulsed MFC cells tumor lysate.

Construction of Oxidative Mannan-conjugated Adenovirus-mcyclin B1 and Induction of Anti-tumor Effect in Vivo

Construction of Antisense c-myc Recombinant Adenovirus and Its Anti-tumor Effects on Osteosarcoma Cell Lines MG-63 and U2OS

Adenovirus-Mediated Small Hairpin Rna Targeting Bcl-Xl As Therapy For Colon Cancer

Therapeutic Effect of MIP-1alpha-recruited Dendritic Cells on Preestablished Solid and Metastatic Tumors.

Immune Adjuvant Targeting Micelles Allow Efficient Dendritic Cell Migration to Lymph Nodes for Enhanced Cellular Immunity.

Construction of Htert and Cox-2 Dependent Oncolytic Adenovirus

The Construction and Characterization of a Novel Adenovirus Vector of Artificial Microrna Targeting EGFR.

Preparation of murine lung cancer vaccine modified by macrophagic inflammatory protein 1αand observational study of antitumor activity in vivo

Construction of a cascade nanosystem to implement indirect and direct cell modulation for tumor microenvironment immunostimulation

CONSTRUCTION OF RECOMBINANT ADENOVIRUS VECTOR BY C-MYC SILENCING

Dendritic Cells Serve As a "trojan Horse" for Oncolytic Adenovirus Delivery in the Treatment of Mouse Prostate Cancer.

Immunotherapy of Tumors with Recombinant Adenovirus Encoding Macrophage Inflammatory Protein 3β Induces Tumor-Specific Immune Response in Immunocompetent Tumor-Bearing Mice

Anti-gastric carcinoma efficacy of gene modified dendritic cell vaccine recruited by macrophage inflammation protein-1

Oncolytic Adenovirus Armed with a Novel Agonist of the CD137 Immune Checkpoint Stimulator Suppresses Tumor Growth

Intratumoral delivery of a novel oncolytic adenovirus encoding human antibody against PD-1 elicits enhanced antitumor efficacy

A Novel Immunocompetent Murine Tumor Model for the Evaluation of RCAd-enhanced RDAd Transduction Efficacy

Oncolytic Adenovirus Programmed by Synthetic Gene Circuit for Cancer Immunotherapy

The Immunological Effect of Ad/MDC-VP1 Combined with DNA Vaccine Against Coxsackievirus Infection

Antitumour Immunity Mediated by Mannan-Modified Adenovirus Vectors Expressing VE-cadherin

The Inhibitory Effect of Conditionally Replicating Adenovirus Combined with Mitomycin on the Proliferation of Bladder Cancer Cells

Optimized mobilization of MHC class I- and II- restricted immunity by dendritic cell vaccine potentiates cancer therapy